comparemela.com

Latest Breaking News On - Clinical research division at fred hutch - Page 1 : comparemela.com

Novel chemoimmunotherapy approach shows promise for B-cell acute lymphoblastic leukemia in phase 1 study at Fred Hutch

Novel chemoimmunotherapy approach shows promise for B-cell acute lymphoblastic leukemia in phase 1 study at Fred Hutch
fredhutch.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fredhutch.org Daily Mail and Mail on Sunday newspapers.

Fred hutchBryan cassadayClinical research division at fred hutchFred hutch cancer centerDivision of hematologyUniversity of washingtonClinical research division

Grivas Expands on Key Data From the 2023 ESMO Congress in Urothelial Cancer

Petros Grivas, MD, PhD, spotlights key advancements and research in urothelial cancer reported at the 2023 ESMO Congress, detailing findings from the phase 3 CheckMate 901, EV-302/KEYNOTE-A39, and THOR trials.

Petros grivasUniversity of washington school medicineGenitourinary cancers programClinical research division at fred hutchDivision of medical oncologyScience summitMedical oncologyWashington schoolClinical research divisionFred hutchFred hutch cancer centerUrothelial cancer

Grivas Expands on Therapeutic Developments and Future Research Directions in GU Cancers

Petros Grivas, MD, PhD, discusses the role of single-agent and combination PARP inhibitor regimens in prostate cancer, as well as the importance of genetic testing in this setting, the role of adjuvant regimens in resected renal cell carcinoma, and more.

University of washingtonUnited statesEvan hallPetros grivasMichael schweizerLisa tachikiScott tykodiClinical research division at fred hutchGenitourinary cancers programDivision of medical oncologyEuropean medicines agencyUniversity of washington school medicineOnclive stateScience summitClinical research divisionFred hutch

Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer

Improvements in PFS were also seen among patients with brain metastases.

United statesSara hurvitzClinical research division at fred hutchUniversity of washington department medicineDivision of hematologyAntonio breast cancer symposiumClinical research divisionFred hutchWashington department

Dr Sara Hurvitz: Addition of Tucatinib to T-DM1 Improves Outcomes in HER2+ Metastatic Breast Cancer

Sara Hurvitz, MD, FACP, shares insights into the results of the HER2CLIMB-02 trial, which saw patients with HER2-positive breast cancer benefit from the addition of tucatinib to trastuzumab emtansine (T-DM1).

Sara hurvitzUniversity of washingtonClinical research division at fred hutchClinical research divisionFred hutchBreast cancerMetastatic breast cancerHer2 positiveT dm1

vimarsana © 2020. All Rights Reserved.